Silencing the critics: new studies move closer to answering epigenetic questions.
Tuma
Rabiya S
RS
D000107:Acetylation / Q000187:drug effects; D048868:Adaptor Proteins, Signal Transducing; D000818:Animals; D000964:Antimetabolites, Antineoplastic / Q000494:pharmacology*; D001374:Azacitidine / Q000031:analogs & derivatives* / Q000494:pharmacology; D002352:Carrier Proteins; D019175:DNA Methylation / Q000187:drug effects*; D004273:DNA, Neoplasm / Q000187:drug effects; D000077209:Decitabine; D004791:Enzyme Inhibitors / Q000494:pharmacology; D044127:Epigenesis, Genetic; D015972:Gene Expression Regulation, Neoplastic / Q000187:drug effects / Q000235:genetics*; D006657:Histones / Q000235:genetics; D006801:Humans; D000070957:MutL Protein Homolog 1; D009154:Mutation; D009363:Neoplasm Proteins / Q000187:drug effects / Q000235:genetics*; D009369:Neoplasms / Q000188:drug therapy / Q000235:genetics* / Q000378:metabolism; D009687:Nuclear Proteins; D010641:Phenotype
D048868:Adaptor Proteins, Signal Transducing; D000964:Antimetabolites, Antineoplastic; D002352:Carrier Proteins; D004273:DNA, Neoplasm; D004791:Enzyme Inhibitors; D006657:Histones; C501486:MLH1 protein, human; D009363:Neoplasm Proteins; D009687:Nuclear Proteins; D000077209:Decitabine; D000070957:MutL Protein Homolog 1; D001374:Azacitidine